EGFR and colorectal carcinoma: For instance, the epidermal growth factor receptor (EGFR), which is overexpressed in CRC, serves as a target for monoclonal antibodies like cetuximab and panitumumab, as well as tyrosine kinase inhibitors like gefitinib.